Related Experiment Video
Updated: Jul 18, 2026
07:57
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Purine-scaffold Hsp90 inhibitors
1Department of Medicine and Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. chiosisg@mskcc.org
Idrugs : the Investigational Drugs Journal
|November 11, 2006
Summary
Novel purine-scaffold inhibitors targeting Heat Shock Protein 90 (Hsp90) show promise for cancer therapeutics. Research focuses on developing improved Hsp90 inhibitors beyond early clinical candidates like 17-AAG.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Heat Shock Protein 90 (Hsp90) is a crucial molecular chaperone implicated in various cancer cell transformations.
- Early Hsp90 inhibitors, such as 17-AAG, demonstrated clinical activity but also revealed limitations.
- There is a significant need for novel Hsp90 inhibitors with enhanced structural and pharmacological properties for cancer treatment.
Purpose of the Study:
- To describe the purine-scaffold class of Hsp90 inhibitors.
- To highlight research from discovery to clinical translation of these compounds.
- To explore potential advancements in cancer therapeutics targeting Hsp90.
Main Methods:
- Review of research on purine-scaffold Hsp90 inhibitors.
- Analysis of drug discovery and development stages.
- Focus on clinical translation efforts.
Main Results:
- Purine-scaffold compounds represent a promising class of Hsp90 inhibitors.
- Ongoing research aims to overcome limitations of earlier Hsp90 inhibitors.
- Development is progressing from discovery through preclinical and clinical stages.
Conclusions:
- Purine-scaffold Hsp90 inhibitors offer a potential new avenue for cancer therapy.
- Continued research is vital for optimizing these inhibitors for clinical use.
- Targeting Hsp90 remains a key strategy in developing novel anti-cancer drugs.
